The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe.

Quality of Life

Ascites has a dramatic impact on the quality of life of those affected patients.
When we were developing the alfapump® system our goal was simple: develop an automated system to eliminate the need for repeated invasive procedures helping to keep patients out of the hospital and live a more free and independent life.

Patients we interviewed that had been implanted with the alfapump® reported that they were eating, breathing and sleeping better; were able to cook for their family again, go on vacation without worrying about getting back in time for the paracentesis; feeling strong enough to do anything they wanted to do. Also their family members experienced a big change and were able to enjoy life together again.